Skip to search formSkip to main contentSkip to account menu
  • Publications
  • Influence
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus
TLDR
RNA sequencing in primary human hepatocytes activated with synthetic double-stranded RNA to mimic HCV infection provides new insights into the genetic regulation of HCV clearance and its clinical management.
View on Nature
ACG Clinical Guideline: The Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury
TLDR
This ACG Clinical Guideline is presented an evidence-based approach to diagnosis and management of DILI with special emphasis on DILi due to herbal and dietary supplements and DilI occurring in individuals with underlying liver disease.
View on Nature
Recommendations for the Diagnosis and Treatment of the Acute Porphyrias
TLDR
The panel, which represents specialties including internal medicine, pediatrics, genetics, gastroenterology, hepatology, and hematology, was charged with formulating updated recommendations for diagnosing and treating the acute porphyrias, issued recommendations based on the specific enzyme and gene defects identified.
View on PubMed
Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States.
TLDR
This report summarizes the causes, clinical features, and outcomes from the first 300 patients enrolled in a prospective study to recruit patients with suspected idiosyncratic drug-induced liver injury and create a repository of biological samples for analysis.
View on PubMed
Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study.
TLDR
Mortality from DILI is significantly higher in individuals with pre-existing liver disease or concomitant severe skin reactions compared with patients without, and additional studies are needed to confirm the association between azithromycin and increased DILi in patients with chronic liver disease.
View on PubMed
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment.
BACKGROUND & AIMS The most effective therapy currently available for treatment of chronic hepatitis C virus (HCV) is the combination of peginterferon and ribavirin. This study evaluated the…
View on PubMed
Vascular Endothelium As a Contributor of Plasma Sphingosine 1-Phosphate
Sphingosine 1-phosphate (S1P), an abundant lipid mediator in plasma, regulates vascular and immune cells by activating S1P receptors. In this report, we investigated the mechanisms by which high…
View on Wolters Kluwer
Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: Results of the HALT‐C cohort
TLDR
A model based on standard laboratory test results can be used to predict histological cirrhosis with a high degree of accuracy in 50% of patients with CHC.
View on Wiley
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease.
TLDR
It was found that maintenance peginterferon did not reduce the incidence of HCC in the HALT-C cohort, and baseline clinical and laboratory features predicted risk for HCC.
View on PubMed
Outcome of sustained virological responders with histologically advanced chronic hepatitis C
TLDR
Patients with advanced chronic hepatitis C who achieved SVR had a marked reduction in death/liver transplantation, and in liver‐related morbidity/mortality, although they remain at risk for HCC.
View on Wiley
...
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License